EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

Weam Othman Elbezanti, Kishore B Challagundla, Subash C Jonnalagadda iD, Tulin Budak-Alpdogan iD, Manoj K Pandey iD

Pharmaceuticals · 08.03.2023 · 16 (3) · 415

DOI: 10.3390/ph16030415 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 08.03.2023. Verfasst von Weam Othman Elbezanti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Cooper Medical School of Rowan University, 401S Broadway, Camden, NJ 08103, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Camden Research Initiative fund, New Jersey Health Foundation, Cooper Medical School of Rowan University, Camden, NJ.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.

Schlagwörter

Stichwörter der Autor:innen

B-cell malignancybone marrow microenvironmentdrug resistanceimmunotherapiesmultiple myelomaproteasome inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Cooper Medical School of Rowan University, 401S Broadway, Camden, NJ 08103, USA.
  • Department of Hematology, MD Anderson Cancer Center at Cooper, Cooper Health System, Camden, NJ 08103, USA.
  • Department of Biochemistry and Molecular Biology, The Fred and Pamela Buffett Cancer Center, The Child Health Research Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Department of Chemistry and Biochemistry, Rowan University, Glassboro, NJ 08028, USA.

ORCID-Profile: Subash C Jonnalagadda, Tulin Budak-Alpdogan, Manoj K Pandey

Förderung

  • Camden Research Initiative fund
  • New Jersey Health Foundation
  • Cooper Medical School of Rowan University, Camden, NJ

Zitieren

APA

Elbezanti, W. O., Challagundla, K. B., Jonnalagadda, S. C., Budak-Alpdogan, T., & Pandey, M. K. (2023). Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals, 16(3), 415. https://doi.org/10.3390/ph16030415

Vancouver

Elbezanti WO, Challagundla KB, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals. 2023;16(3):415. doi:10.3390/ph16030415

BibTeX
@article{Elbezanti2023,
  author = {Elbezanti, Weam Othman and Challagundla, Kishore B and Jonnalagadda, Subash C and Budak-Alpdogan, Tulin and Pandey, Manoj K},
  title = {Past, Present, and a Glance into the Future of Multiple Myeloma Treatment},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {3},
  pages = {415},
  doi = {10.3390/ph16030415}
}
Kostenlos starten →